Cancers 2011, 3(3), 3419-3431; doi:10.3390/cancers3033419
Article

Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre

1 Austin Health Radiation Oncology Centre, Heidelberg Repatriation Hospital, 300 Waterdale Road, Heidelberg West, Victoria 3081, Australia 2 Radiation Oncology Victoria, East Melbourne, Victoria 3002, Australia 3 Department of Medicine, University of Melbourne, Melbourne Victoria 3053, Australia 4 Royal Marsden Hospital & Institute of Cancer Research, London SW3 6JJ, UK
* Author to whom correspondence should be addressed.
Received: 15 August 2011; in revised form: 24 August 2011 / Accepted: 25 August 2011 / Published: 1 September 2011
(This article belongs to the Special Issue Radiation and Cancers)
PDF Full-text Download PDF Full-Text [341 KB, uploaded 1 September 2011 13:43 CEST]
Abstract: Purpose: To report the toxicity and long-term outcomes of dose-escalated intensity-modulated radiation therapy (IMRT) for patients with localised prostate cancer. Methods and Materials: From 2001 to 2005, a total of 125 patients with histologically confirmed T1-3N0M0 prostate cancer were treated with IMRT to 74Gy at the Austin Health Radiation Oncology Centre. The median follow-up was 5.5 years (range 0.5–8.9 years). Biochemical prostate specific antigen (bPSA) failure was defined according to the Phoenix consensus definition (absolute nadir + 2ng/mL). Toxicity was scored according to the RTOG/EORTC criteria. Kaplan-Meier analysis was used to calculate toxicity rates, as well as the risks of bPSA failure, distant metastases, disease-specific and overall survival, at 5 and 8-years post treatment. Results: All patients completed radiotherapy without any treatment breaks. The 8-year risks of ≥ Grade 2 genitourinary (GU) and gastrointestinal (GI) toxicity were 6.4% and 5.8% respectively, and the 8-year risks of ≥ Grade 3 GU and GI toxicity were both < 0.05%. The 5 and 8-year freedom from bPSA failure were 76% and 58% respectively. Disease-specific survival at 5 and 8 years were 95% and 91%, respectively, and overall survival at 5 and 8 years were 90% and 71%, respectively. Conclusions: These results confirm existing international data regarding the safety and efficacy of dose-escalated intensity-modulated radiation therapy for localised prostate cancer within an Australian setting.
Keywords: dose escalation; IMRT; late effects; prostate cancer; toxicity; radiation

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Sia, J.; Joon, D.L.; Viotto, A.; Mantle, C.; Quong, G.; Rolfo, A.; Wada, M.; Anderson, N.; Rolfo, M.; Khoo, V. Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre. Cancers 2011, 3, 3419-3431.

AMA Style

Sia J, Joon DL, Viotto A, Mantle C, Quong G, Rolfo A, Wada M, Anderson N, Rolfo M, Khoo V. Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre. Cancers. 2011; 3(3):3419-3431.

Chicago/Turabian Style

Sia, Joseph; Joon, Daryl Lim; Viotto, Angela; Mantle, Carmel; Quong, George; Rolfo, Aldo; Wada, Morikatsu; Anderson, Nigel; Rolfo, Maureen; Khoo, Vincent. 2011. "Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre." Cancers 3, no. 3: 3419-3431.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert